Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Co-authors
(26)
Tomislav Dragovich
2
Lynn Kirkpatrick
2
Ramesh K. Ramanathan
2
Ann Lowe
1
Glen J. Weiss
1
Journals
(4)
EJC SUPPL
2
CANCER CHEMOTHER PHARMACOL
1
J TRANSL MED
1
INVEST NEW DRUG
1
Keywords
(22)
Embed
Subscribe
Academic
Authors
Linda A. Pestano
Linda A. Pestano,University of Arizona,Oncology,Pharmacology
Edit
Linda A. Pestano
University of Arizona
Publications:
5
|
Citations:
3
Fields:
Oncology
,
Pharmacology
View FAQ about top research areas and Fields of study
Collaborated with
26 co-authors
from 2003 to 2011
|
Cited by
14 authors
Cumulative
Annual
Sort by:
Publications
(5)
BibTeX
|
RIS
|
RefWorks
Download
A randomized phase II study of PX12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination
(
Citations: 1
)
Ramesh K. Ramanathan
,
James Abbruzzese
,
Tomislav Dragovich
,
Lynn Kirkpatrick
,
Jose M. Guillen
,
Amanda F. Baker
,
Linda A. Pestano
,
Sylvan Green
,
Daniel D. Von Hoff
Journal:
Cancer Chemotherapy and Pharmacology - CANCER CHEMOTHER PHARMACOL
, vol. 67, no. 3, pp. 503-509, 2011
108 POSTER Screening Plasma Thioredoxin1 (Trx-1) to potentially guide clinical development of the Trx-1 Inhibitor PX12
D. L. Kirkpatrick
,
A. Hiscox
,
M. Boice
,
D. Swanlund
,
L. Baronic
,
L. Pestano
Journal:
Ejc Supplements - EJC SUPPL
, vol. 6, no. 12, pp. 36-36, 2008
99 POSTER Phase IB trial of PX12 delivered as a 24-hr infusion in patients with advanced gastrointestinal malignancies
T. Dragovich
,
D. Rensvold
,
S. Wood
,
L. Pestano
,
T. Hysyong
,
L. Kirpatrick
Journal:
Ejc Supplements - EJC SUPPL
, vol. 4, no. 12, pp. 34-34, 2006
Interferon-γ Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses
(
Citations: 2
)
Gopi Shankar
,
Linda A Pestano
,
Marnix L Bosch
Journal:
Journal of Translational Medicine - J TRANSL MED
, vol. 1, no. 1, pp. 7-12, 2003
A phase I trial of PX12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy
Ramesh K. Ramanathan
,
Joe J. Stephenson
,
Glen J. Weiss
,
Linda A. Pestano
,
Ann Lowe
,
Alton Hiscox
,
Rafael A. Leos
,
Julie C. Martin
,
Lynn Kirkpatrick
,
Donald A. Richards
Journal:
Investigational New Drugs - INVEST NEW DRUG
, pp. 1-6
Sort by:
Citations
(3 times by 3 publications)
Differential expression of CD5 on B lymphocytes in cattle infected with Mycobacterium avium subsp. paratuberculosis
(
Citations: 1
)
J. R. Stabel
,
M. S. Khalifeh
Journal:
Veterinary Immunology and Immunopathology - VET IMMUNOL IMMUNOPATHOL
, vol. 126, no. 3, pp. 211-219, 2008
DENDRITIC CELL BASED VACCINES: PROGRESS IN IMMUNOTHERAPY STUDIES FOR PROSTATE CANCER
(
Citations: 25
)
HAAKON RAGDE
,
WILLIAM A. CAVANAGH
,
BENJAMIN A. TJOA
Journal:
Journal of Urology - J UROL
, vol. 172, no. 6, pp. 2532-2538, 2004
A phase I trial of PX12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy
Ramesh K. Ramanathan
,
Joe J. Stephenson
,
Glen J. Weiss
,
Linda A. Pestano
,
Ann Lowe
,
Alton Hiscox
,
Rafael A. Leos
,
Julie C. Martin
,
Lynn Kirkpatrick
,
Donald A. Richards
Journal:
Investigational New Drugs - INVEST NEW DRUG
, pp. 1-6
Comments